Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorEfferon JSC

About this trial

Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction.

Cardiogenic shock is a well-known and potent trigger of the immune response, ischemia/reperfusion organ damage, hemolysis and release of free hemoglobin. The activation of immune cells leads to the release of cytokines and inflammatory mediators such as IL-6, IL-8, activated complement and others. As a result of myocardial ischaemia and reperfusion injury, a multiorgan dysfunction syndrome may develop.

The Efferon CT hemoadsorption device effectively removes cytokines and other pro-inflammatory molecules (≤55 kDa). This study evaluates whether this blood-filtering therapy can prevent organ failure in acute myocardial infarction patients with cardiogenic shock by eliminating inflammation-inducing mediators.

Eligibility criteria

Qualifiers

Not more than 4 hours after diagnosis Cardiogenic shock complicating acute myocardial infarction

Stages B - C of cardiogenic shock according to SCAI

Patient condition allows treatment with Efferon® CT device for at least 4 hours

SOFA score 12 or less

Disqualifiers

Broken-heart syndrome (takotsubo cardiomyopathy)

Postcardiotomy cardiogenic shock

Acute myocardial infarction within the last 4 weeks

Myocarditis

Trial design

Treatments tested in this trial

  • Efferon CT

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators